Mifepristone now available through the Inter-Agency Reproductive Health Kits!



With the 2018 revision of the Inter-Agency Field Manual (IAFM) on Reproductive Health in Humanitarian Settings to include safe abortion as an additional priority in the Minimum Initial Service Package (MISP), mifepristone has been added as a complementary commodity to Kit 8 of the Reproductive Health (RH) kits (http://iawg.net/wp-content/uploads/2019/01/MISP-Cheatsheet.pdf).

Complementary commodities are a set of disposable and consumable items and/or kits that can be ordered in specific circumstances to complement existing RH kits where:

- providers are trained to use the special supply;
- the supplies were accepted and used prior to the emergency;
- in protracted or post-acute settings (although efforts must be directed to procuring from more stable procurement channels); and
- where the use of the supplies is allowed to the fullest extent of the national law.

Product cost and packaging data are coming soon from UNFPA.

How to order Inter-Agency RH Kits:

Procurement Services Branch Marmorvej 51 2100 Copenhagen, Denmark

procurement@unfpa.org www.unfpaprocurement.org/ humanitarian-supplies



Dosing regimens from the World Health Organization

Mifepristone combined with misoprostol is the gold standard combination for abortion with medicines recommended by the Word Health Organization (WHO). Where mifepristone is not available, misoprostol can be used alone, though it is less effective. Misoprostol is already available in Inter-Agency RH Kit 8 (Management of complications of miscarriage or abortion) and is already widely available in most countries. Additional misoprostol may also be ordered from the complementary commodities.

MIFEPRISTONE AND MISOPROSTOL REGIMEN FOR ABORTION UP TO 12 WEEKS GESTATION	
MIFEPRISTONE DOSE	MISOPROSTOL DOSE, ROUTE AND TIMING
200mg orally	800mcg buccally, sublingually or vaginally 1-2 days after mifepristone*
MISOPROSTOL-ONLY REGIMEN FOR ABORTION UP TO 12 WEEKS GESTATION	
800mcg buccally, sublingually or vaginally*	
*Repeat doses of misoprostol can be considered to achieve success of the abortion process.	

Source: World Health Organization. (2018). Medical management of abortion. Geneva: WHO. www.who.int/reproductivehealth/publications/ medical-management-abortion/en

Important note: After the IAFM was published, the WHO released updated guidance on medical management of abortion in which the regimens were simplified. While the regimens in the IAFM are not incorrect, the newest guidance from WHO is listed here for simplicity.

For more information on how to use medicines for abortion, see "Chapter 8: Comprehensive Abortion Care" in the IAFM: http://iawg.net/iafm